文献速递临床试验与 GCP

乌帕替尼改善阿达木单抗治疗的银屑病关节炎患者焦虑:随机对照试验研究方案

Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-09-05

本研究为12周随机开放标签对照试验,将合并焦虑的银屑病关节炎患者按1:1随机分配至乌帕替尼组(每日15 mg)或阿达木单抗组(每2周40 mg),主要结局为12周后医院焦虑自评量表(HADS-A)总分变化,次要结局包括HAQ-DI变化、ACR20达标率和sPGA 0/1达标率。

要点

  • 乌帕替尼对银屑病关节炎患者焦虑的影响尚不确定,本研究旨在提供见解。
  • 主要结局为12周后HADS-A总分变化,采用单因素方差分析比较组间均值。
  • 试验注册号ChiCTR2400079755,2024年1月11日注册于ChiCTR。

核心结论

  • 乌帕替尼对银屑病关节炎患者焦虑的影响仍不确定,本12周开放随机对照试验旨在提供疾病进展的见解,并强调治疗期间处理银屑病关节炎相关焦虑的重要性。

研究设计与样本

  • 12周随机、开放标签、对照试验,将合并焦虑的银屑病关节炎患者按1:1比例随机分配至乌帕替尼组或阿达木单抗组。
  • 乌帕替尼组每日剂量15 mg,阿达木单抗组每2周40 mg。

主要发现

  • 主要结局为12周干预后医院焦虑自评量表(HADS-A)总分变化。
  • 次要结局包括健康评估问卷-残疾指数(HAQ-DI)变化、12周后达到ACR20标准的参与者百分比、以及第12周银屑病静态研究者总体评估(sPGA)达到0或1级且较基线改善至少2分的参与者百分比(sPGA 0/1)。
  • 采用单因素方差分析(ANOVA)比较乌帕替尼组与阿达木单抗组间正态分布变量的均值。

局限性

  • 乌帕替尼对银屑病关节炎患者焦虑的影响仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psoriatic arthritis (PsA) often suffer from anxiety disorders. While upadacitinib has shown effectiveness in reducing various disease activity indicators in active PsA, its impact on anxiety disorders in PsA patients needs further investigation. METHODS: In this 12-week randomized, open-label, controlled trial, PsA patients with coexisting anxiety were randomly assigned to either the upadacitinib group or the adalimumab group in a 1:1 ratio. The upadacitinib group received a daily dose of 15 mg, while the adalimumab group received 40 mg every 2 weeks. The primary outcome measured the change in Hospital Anxiety Self-Assessment Scale (HADS-A) total scores after the 12-week intervention. Secondary outcomes included changes in the Health Assessment Questionnaire-Disability Index (HAQ-DI), the percentage of participants meeting the ACR20 criteria compared to baseline after 12 weeks, and the percentage of participants achieving a grade 0 or 1 in the psoriasis static Investigator's overall assessment (sPGA) at week 12 with an improvement of at least 2 points from baseline (sPGA 0/1). One-way analysis of variance (ANOVA) was used to compare the means of normally distributed variables between the upadacitinib and adalimumab groups. DISCUSSION: The impact of upadacitinib on anxiety in PsA patients remains uncertain. This 12-week open randomized controlled trial aims to provide insights into disease progression and underscore the importance of addressing PsA-related anxiety during treatment. TRIAL REGISTRATION: ChiCTR2400079755. Registered on January 11, 2024, with ChiCTR. https://www.chictr.org.cn/showproj.html?proj=216538.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Liao J, Wang Z, Zhang J, et al. Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial. Trials. 2024. PMID: 39238035. doi:10.1186/s13063-024-08429-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。